Skip to main content

Advertisement

SpringerLink
Log in

Real-World Data of the Correlation between EGFR Determination by Liquid Biopsy in Non-squamous Non-small Cell Lung Cancer (NSCLC) and the EGFR Profile in Tumor Biopsy

  • Original Article
  • Published:
Pathology & Oncology Research

Abstract

EGFR-mutated non-small cell lung cancer (NSCLC) has significant improved outcomes when treated with EGFR-tyrosine kinase inhibitors (TKI). Thus, EGFR-mutational status should be assessed at diagnosis and in the course of treatment with TKI. However, tissue samples are not always evaluable, and molecular profiling has been increasingly performed in cell-free tumor DNA (ctDNA) from blood samples. Our objective is to evaluate the reliability of ctDNA profiling in plasma samples in a real-world setting. We retrospectively analyzed the patients diagnosed with non-squamous NSCLC from May 2016 to December 2017 at Hospital Universitario Doctor Peset who had been tested for EGFR mutations in tissue and plasma samples. Both samples were sent to an external laboratory to perform the analysis by the cobas® EGFR assay. Percentage of agreement and concordance were calculated by kappa statistic. Of 102 patients reviewed, 89 were eligible. The overall EGFR mutation frequency was 18.6% for the evaluable tissue samples and 19.6% for evaluable plasma samples. Mutation status concordance between matched samples was 87.4%. Cohen’s kappa index (κ) = 0.6 (sensitivity 70.6%, specificity 91.7%, positive predictive value 66.7%, negative predictive value 93%). When concordance was stablished only in stage IV tumors κ = 0.7, suggesting a higher agreement in advanced disease. This real-world data suggest that plasma is a feasible sample for ctDNA EGFR mutation assessment. Results of ctDNA molecular profiling are reliable when using a validated technique such as the cobas® EGFR assay, especially in patients that cannot undergo a tissue biopsy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Cancer Incidence IARC (2012) Mortality and prevalence worldwide. In: GLOBOCAN

    Google Scholar 

  2. Malvezzi M, Carioli G, Bertuccio P, Boffetta P, Levi F, La Vecchia C et al (2017) European cancer mortality predictions for the year 2017, with focus on lung cancer. Ann Oncol 28:1117–1123. https://doi.org/10.1093/annonc/mdx033

    Article  CAS  PubMed  Google Scholar 

  3. Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, Majem M, Lopez-Vivanco G, Isla D, Provencio M, Insa A, Massuti B, Gonzalez-Larriba JL, Paz-Ares L, Bover I, Garcia-Campelo R, Moreno MA, Catot S, Rolfo C, Reguart N, Palmero R, Sánchez JM, Bastus R, Mayo C, Bertran-Alamillo J, Molina MA, Sanchez JJ, Taron M (2009) Screening for epidermal growth factor receptor mutations in lung Cancer. N Engl J Med 361:958–967. https://doi.org/10.1056/NEJMoa0904554

    Article  CAS  PubMed  Google Scholar 

  4. Janku F, Angenendt P, Tsimberidou AM, Fu S, Naing A, Falchook GS, Hong DS, Holley VR, Cabrilo G, Wheler JJ, Piha-Paul SA, Zinner RG, Bedikian AY, Overman MJ, Kee BK, Kim KB, Kopetz SE, Luthra R, Diehl F, Meric-Bernstam F, Kurzrock R (2015) Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies. Oncotarget 6:12809–12821. https://doi.org/10.18632/oncotarget.3373

    Article  PubMed  PubMed Central  Google Scholar 

  5. Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, Bartlett BR, Wang H, Luber B, Alani RM, Antonarakis ES, Azad NS, Bardelli A, Brem H, Cameron JL, Lee CC, Fecher LA, Gallia GL, Gibbs P, le D, Giuntoli RL, Goggins M, Hogarty MD, Holdhoff M, Hong SM, Jiao Y, Juhl HH, Kim JJ, Siravegna G, Laheru DA, Lauricella C, Lim M, Lipson EJ, Marie SKN, Netto GJ, Oliner KS, Olivi A, Olsson L, Riggins GJ, Sartore-Bianchi A, Schmidt K, Shih M, Oba-Shinjo SM, Siena S, Theodorescu D, Tie J, Harkins TT, Veronese S, Wang TL, Weingart JD, Wolfgang CL, Wood LD, Xing D, Hruban RH, Wu J, Allen PJ, Schmidt CM, Choti MA, Velculescu VE, Kinzler KW, Vogelstein B, Papadopoulos N, Diaz LA (2014) Detection of circulating tumor DNA in early and late stage human malignancies. Sci Transl Med 6:224ra24. https://doi.org/10.1126/scitranslmed.3007094

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WEE, Nicholson AG, Groome P, Mitchell A, Bolejack V, Goldstraw P, Rami-Porta R, Asamura H, Ball D, Beer DG, Beyruti R, Bolejack V, Chansky K, Crowley J, Detterbeck F, Erich Eberhardt WE, Edwards J, Galateau-Sallé F, Giroux D, Gleeson F, Groome P, Huang J, Kennedy C, Kim J, Kim YT, Kingsbury L, Kondo H, Krasnik M, Kubota K, Lerut A, Lyons G, Marino M, Marom EM, van Meerbeeck J, Mitchell A, Nakano T, Nicholson AG, Nowak A, Peake M, Rice T, Rosenzweig K, Ruffini E, Rusch V, Saijo N, van Schil P, Sculier JP, Shemanski L, Stratton K, Suzuki K, Tachimori Y, Thomas CF Jr, Travis W, Tsao MS, Turrisi A, Vansteenkiste J, Watanabe H, Wu YL, Baas P, Erasmus J, Hasegawa S, Inai K, Kernstine K, Kindler H, Krug L, Nackaerts K, Pass H, Rice D, Falkson C, Filosso PL, Giaccone G, Kondo K, Lucchi M, Okumura M, Blackstone E, Abad Cavaco F, Ansótegui Barrera E, Abal Arca J, Parente Lamelas I, Arnau Obrer A, Guijarro Jorge R, Ball D, Bascom GK, Blanco Orozco AI, González Castro MA, Blum MG, Chimondeguy D, Cvijanovic V, Defranchi S, de Olaiz Navarro B, Escobar Campuzano I, Macía Vidueira I, Fernández Araujo E, Andreo García F, Fong KM, Francisco Corral G, Cerezo González S, Freixinet Gilart J, García Arangüena L, García Barajas S, Girard P, Goksel T, González Budiño MT, González Casaurrán G, Gullón Blanco JA, Hernández Hernández J, Hernández Rodríguez H, Herrero Collantes J, Iglesias Heras M, Izquierdo Elena JM, Jakobsen E, Kostas S, León Atance P, Núñez Ares A, Liao M, Losanovscky M, Lyons G, Magaroles R, de Esteban Júlvez L, Mariñán Gorospe M, McCaughan B, Kennedy C, Melchor Íñiguez R, Miravet Sorribes L, Naranjo Gozalo S, Álvarez de Arriba C, Núñez Delgado M, Padilla Alarcón J, Peñalver Cuesta JC, Park JS, Pass H, Pavón Fernández MJ, Rosenberg M, Ruffini E, Rusch V, Sánchez de Cos Escuín J, Saura Vinuesa A, Serra Mitjans M, Strand TE, Subotic D, Swisher S, Terra R, Thomas C, Tournoy K, van Schil P, Velasquez M, Wu YL, Yokoi K (2016) The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol 11:39–51. https://doi.org/10.1016/j.jtho.2015.09.009

    Article  PubMed  Google Scholar 

  7. Viera AJ, Garrett JM (2005) Understanding interobserver agreement: the kappa statistic. Fam Med 37:360–363

    PubMed  Google Scholar 

  8. Planchard D, Popat S, Kerr K, Novello S, Smit E, Faivre-Finn C et al (2018) Metastatic non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up†. Ann Oncol 27:v192–v237. https://doi.org/10.1093/annonc/mdw326.

    Article  Google Scholar 

  9. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM, Porta R, Cobo M, Garrido P, Longo F, Moran T, Insa A, de Marinis F, Corre R, Bover I, Illiano A, Dansin E, de Castro J, Milella M, Reguart N, Altavilla G, Jimenez U, Provencio M, Moreno MA, Terrasa J, Muñoz-Langa J, Valdivia J, Isla D, Domine M, Molinier O, Mazieres J, Baize N, Garcia-Campelo R, Robinet G, Rodriguez-Abreu D, Lopez-Vivanco G, Gebbia V, Ferrera-Delgado L, Bombaron P, Bernabe R, Bearz A, Artal A, Cortesi E, Rolfo C, Sanchez-Ronco M, Drozdowskyj A, Queralt C, de Aguirre I, Ramirez JL, Sanchez JJ, Molina MA, Taron M, Paz-Ares L (2012) Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13:239–246. https://doi.org/10.1016/S1470-2045(11)70393-X

    Article  CAS  Google Scholar 

  10. Sequist LV, Yang JC-H, Yamamoto N, O’Byrne K, Hirsh V, Mok T et al (2013) Phase III study of Afatinib or cisplatin plus Pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 31:3327–3334. https://doi.org/10.1200/JCO.2012.44.2806

    Article  CAS  PubMed  Google Scholar 

  11. Oxnard GR, Arcila ME, Sima CS, Riely GJ, Chmielecki J, Kris MG, Pao W, Ladanyi M, Miller VA (2011) Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation. Clin Cancer Res 17:1616–1622. https://doi.org/10.1158/1078-0432.CCR-10-2692

    Article  CAS  PubMed  Google Scholar 

  12. Goss G, Tsai CM, Shepherd FA, Bazhenova L, Lee JS, Chang GC, Crino L, Satouchi M, Chu Q, Hida T, Han JY, Juan O, Dunphy F, Nishio M, Kang JH, Majem M, Mann H, Cantarini M, Ghiorghiu S, Mitsudomi T (2016) Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol 17:1643–1652. https://doi.org/10.1016/S1470-2045(16)30508-3

    Article  CAS  PubMed  Google Scholar 

  13. Rolfo C, Mack PC, Scagliotti GV, Baas P, Barlesi F, Bivona TG, Herbst RS, Mok TS, Peled N, Pirker R, Raez LE, Reck M, Riess JW, Sequist LV, Shepherd FA, Sholl LM, Tan DSW, Wakelee HA, Wistuba II, Wynes MW, Carbone DP, Hirsch FR, Gandara DR (2018) Liquid biopsy for advanced non-small cell lung Cancer (NSCLC): a statement paper from the IASLC. J Thorac Oncol 13:1248–1268. https://doi.org/10.1016/j.jtho.2018.05.030

    Article  PubMed  Google Scholar 

  14. Malapelle U, Sirera R, Jantus-Lewintre E, Reclusa P, Calabuig-Fariñas S, Blasco A, Pisapia P, Rolfo C, Camps C (2017) Profile of the Roche cobas® EGFR mutation test v2 for non-small cell lung cancer. Expert Rev Mol Diagn 17:209–215. https://doi.org/10.1080/14737159.2017.1288568

    Article  CAS  PubMed  Google Scholar 

  15. Reckamp KL, Melnikova VO, Karlovich C, Sequist LV, Camidge DR, Wakelee H, Perol M, Oxnard GR, Kosco K, Croucher P, Samuelsz E, Vibat CR, Guerrero S, Geis J, Berz D, Mann E, Matheny S, Rolfe L, Raponi M, Erlander MG, Gadgeel S (2016) A highly sensitive and quantitative test platform for detection of NSCLC EGFR mutations in urine and plasma. J Thorac Oncol 11:1690–1700. https://doi.org/10.1016/j.jtho.2016.05.035

    Article  PubMed  Google Scholar 

  16. Douillard JY, Ostoros G, Cobo M, Ciuleanu T, Cole R, McWalter G, Walker J, Dearden S, Webster A, Milenkova T, McCormack R (2014) Gefitinib treatment in EGFR mutated caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR status. J Thorac Oncol 9:1345–1353. https://doi.org/10.1097/JTO.0000000000000263

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Soria J-C, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH et al (2018) Osimertinib in untreated EGFR -mutated advanced non–small-cell lung Cancer. N Engl J Med 2017:NEJMoa1713137. https://doi.org/10.1056/NEJMoa1713137

    Article  Google Scholar 

  18. Han B, Tjulandin S, Hagiwara K, Normanno N, Wulandari L, Laktionov K, Hudoyo A, He Y, Zhang YP, Wang MZ, Liu CY, Ratcliffe M, McCormack R, Reck M (2017) EGFR mutation prevalence in Asia-Pacific and Russian patients with advanced NSCLC of adenocarcinoma and non-adenocarcinoma histology: the IGNITE study. Lung Cancer 113:37–44. https://doi.org/10.1016/j.lungcan.2017.08.021

    Article  PubMed  Google Scholar 

  19. Wu Y-L, Sequist LV, Hu C-P, Feng J, Lu S, Huang Y, Li W, Hou M, Schuler M, Mok T, Yamamoto N, O'Byrne K, Hirsh V, Gibson N, Massey D, Kim M, Yang JCH (2016) EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-lung 3 and 6. Br J Cancer 116:175–185. https://doi.org/10.1038/bjc.2016.420

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Reck M, Hagiwara K, Han B, Tjulandin S, Grohé C, Yokoi T, Morabito A, Novello S, Arriola E, Molinier O, McCormack R, Ratcliffe M, Normanno N (2016) CtDNA determination of EGFR mutation status in European and Japanese patients with advanced NSCLC: the ASSESS study. J Thorac Oncol 11:1682–1689. https://doi.org/10.1016/j.jtho.2016.05.036

    Article  PubMed  Google Scholar 

  21. Esteban E, Majem M, Martinez Aguillo M, Martinez Banaclocha N, Dómine M, Gómez Aldaravi L, Juan O, Cajal R, Gonzalez Arenas MC, Provencio M (2015) Prevalence of EGFR mutations in newly diagnosed locally advanced or metastatic non-small cell lung cancer Spanish patients and its association with histological subtypes and clinical features: the Spanish REASON study. Cancer Epidemiol 39:291–297. https://doi.org/10.1016/j.canep.2015.02.003

    Article  CAS  PubMed  Google Scholar 

  22. Normanno N, Denis MG, Thress KS, Ratcliffe M, Reck M (2017) Guide to detecting epidermal growth factor receptor (EGFR) mutations in ctDNA of patients with advanced non-small-cell lung cancer. Oncotarget 8:12501–12516. https://doi.org/10.18632/oncotarget.13915

    Article  PubMed  Google Scholar 

  23. Crowley E, Di Nicolantonio F, Loupakis F, Bardelli A (2013) Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol 10:472–484. https://doi.org/10.1038/nrclinonc.2013.110

    Article  CAS  PubMed  Google Scholar 

  24. Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, et al. Liquid biopsies: genotyping circulating tumor DNA. Nat Med 2014;4:224ra24-224ra24. https://doi.org/10.1158/2159-8290.CD-13-1014.Blood.

Download references

Acknowledgements

The authors would like to express our gratitude to Joanna Gołąb for her contribution providing language help for the manuscript.

Author information

Author notes

  1. Teresa Soria-Comes and Vicente Palomar-Abril contributed equally to this work.

Authors and Affiliations

  1. Department of Medical Oncology, Hospital Universitario Doctor Peset, 46017, Comunitat Valenciana, Valencia, Spain

    Teresa Soria-Comes, María Martín Ureste & Inmaculada Concepción Maestu Maiques

  2. Department of Medical Oncology, Hospital Universitario Doctor Peset, Comunitat Valenciana, Valencia, Spain

    Mónica Tallón Guerola

Authors
  1. Teresa Soria-Comes
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Vicente Palomar-Abril
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. María Martín Ureste
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mónica Tallón Guerola
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Inmaculada Concepción Maestu Maiques
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Concept and design of the study: Teresa Soria-Comes, Vicente Palomar-Abril, Inmaculada Concepción Maestu Maiques.

Data collection: Teresa Soria-Comes, Mónica Tallón Guerola, María Martín Ureste.

Analysis and interpretation of data: Teresa Soria-Comes, Vicente Palomar-Abril.

Draft manuscript: Teresa Soria-Comes, Vicente Palomar-Abril.

Critical review of the manuscript: All authors.

Final approval of the manuscript: All authors.

Corresponding author

Correspondence to Teresa Soria-Comes.

Ethics declarations

Informed Consent

The study was conducted in accordance with the Declaration of Helsinki, written informed consent was exempted because of the retrospective nature of the study.

This manuscript has not been published and is not under consideration for publication elsewhere.

Conflict of Interest

The authors declare that they have no conflicts of interest.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Soria-Comes, T., Palomar-Abril, V., Ureste, M.M. et al. Real-World Data of the Correlation between EGFR Determination by Liquid Biopsy in Non-squamous Non-small Cell Lung Cancer (NSCLC) and the EGFR Profile in Tumor Biopsy. Pathol. Oncol. Res. 26, 845–851 (2020). https://doi.org/10.1007/s12253-019-00628-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12253-019-00628-x

Keywords

Search

Navigation